Logo for Scinai Immunotherapeutics Ltd

Scinai Immunotherapeutics Investor Relations Material

Latest events

Logo for Scinai Immunotherapeutics Ltd

Study Update

Scinai Immunotherapeutics
Logo for Scinai Immunotherapeutics

Study Update

18 Sep, 2024
Logo for Scinai Immunotherapeutics

Q2 2024

20 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Scinai Immunotherapeutics Ltd

Access all reports
Scinai Immunotherapeutics Ltd., formerly known as BiondVax Pharmaceuticals Ltd., is an Israeli biopharmaceutical company primarily engaged in the development, manufacture, and commercialization of innovative biological products. The company's focus is on inflammation and immunology, with a particular emphasis on autoimmune and infectious diseases. Scinai's product development pipeline includes a range of nanosized antibodies, known as NanoAbs, derived from alpacas. These antibodies target various diseases with significant unmet medical needs. Additionally, Scinai operates a boutique contract development and manufacturing organization (CDMO) that provides comprehensive services to pharmaceutical, biotech, and alternative protein food tech companies. The company is headquartered in Jerusalem, Israel, and its shares are listed on the NASDAQ.